Updating results

3 results for ta455 Sort: Relevance | Date

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)

Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel) and ustekinumab (Stelara) for treating plaque psoriasis in children and young people

Technology appraisal guidance Published July 2017

Trials that evaluate utility values (using generic preference-based measures) in children and young people with severe psoriasis are needed to better inform future cost–utility analyses.

Recommendation ID TA455/1 Question Trials that evaluate utility values (using generic preference-based measures) in children and young...

Research recommendation Published October 2018

Research recommendations

TA455/1 | Trials that evaluate utility values (using generic preference-based measures)

Published April 2016